SEC Comment Letter for Hepion Pharmaceuticals, Inc. (HEPA, CTRVP) (CIK 0001583771) (HEPA) — Oct 27, 2014
Hepion Pharmaceuticals, Inc. (HEPA, CTRVP) (CIK 0001583771)
Date: Oct. 27, 2014 · CIK: 0001583771 · Accession: 0000000000-14-053378
AI Filing Summary & Sentiment
File numbers found in text: 000-55020
Letter
October 2 7, 2014 Via E -mail Gary S. Jacob Chief Executive Officer and Director ContraVir Pharmaceuticals, Inc. 399 Thornall Street, First Floor Edison, New Jersey 08837
Re: ContraVir Pharmaceuticals, Inc. Preliminary Proxy Statement on Schedule 14 A Filed October 17, 2014 File No. 000-55020
Dear Mr. Jacob :
We have completed our review of your filing. We remind you that our comments or changes to disclosure in response to our comments do not foreclose the Commission from taking any action with r espect to the company or the filing and the company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. We urge all persons who are responsible for the accuracy and adequacy of the disclosure in the filing ] to be certain that the filing includes the information the Securities Exchange Act of 1934 and all applicable rules require.
Sincerely,
/s/ Jeffrey P. Riedler
Show Raw Text
October 2 7, 2014 Via E -mail Gary S. Jacob Chief Executive Officer and Director ContraVir Pharmaceuticals, Inc. 399 Thornall Street, First Floor Edison, New Jersey 08837 Re: ContraVir Pharmaceuticals, Inc. Preliminary Proxy Statement on Schedule 14 A Filed October 17, 2014 File No. 000-55020 Dear Mr. Jacob : We have completed our review of your filing. We remind you that our comments or changes to disclosure in response to our comments do not foreclose the Commission from taking any action with r espect to the company or the filing and the company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. We urge all persons who are responsible for the accuracy and adequacy of the disclosure in the filing ] to be certain that the filing includes the information the Securities Exchange Act of 1934 and all applicable rules require. Sincerely, /s/ Jeffrey P. Riedler Jeffrey P. Riedler Assistant Director cc: Jeffrey Fessler Sichenzia Ross Friedman Ference LLP 61 Broadway, 32nd Floor New York, NY 10006